Toxizitätsmanagement für Antitumoraktivität von Cars
Anmelder: The Trustees of the University of Pennsylvania, The Children's Hospital of Philadelphia 🇺🇸
Details
- Veröffentlichungs-Nr.
- EP4772189
- Anmeldetag
- 12. Juli 2013
- Veröffentlichung
- 8. Juli 2026
- Rechtsraum
- EP
- IPC
- A61K39/00
Abstract
The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.
Anmelder
- Firmen
- The Trustees of the University of Pennsylvania
The Children's Hospital of Philadelphia - Land
- 🇺🇸 USA